Welk v. Nutraceutical Corporation
Filing
25
ORDER granting 15 Motion to Dismiss without prejudice. If Plaintiff elects to amend her pleading, it must be filed no later than August 17, 2018.. Signed by Judge Roger T. Benitez on 8/10/2018. (anh)
1
2
3
4
5
6
7
8
UNITED STATES DISTRICT COURT
9
SOUTHERN DISTRICT OF CALIFORNIA
10
11
12
TONI WELK, Individually and On Behalf
of All Others Similarly Situated,
15
16
ORDER GRANTING MOTION TO
DISMISS
Plaintiff,
13
14
Case No.: 3:17-cv-02266-BEN-KSC
v.
NUTRACEUTICAL CORPORATION,
doing business as Nutrabiogenesis doing
business as Biogenesis,
Defendant.
17
18
19
Before the Court is the motion to dismiss Plaintiff’s First Amended Complaint
20
filed by Defendant Nutraceutical Corporation (“Nutraceutical”). (Docket No. 15.) The
21
motion is fully briefed. For the reasons that follow, the motion is GRANTED.
BACKGROUND1
22
23
Nutraceutical manufactures, distributes, and sells liquid Vitamin B12 as a dietary
24
supplement under different brands and containing different amounts of Vitamin B12 per
25
26
27
28
1
The following overview of the facts is drawn from the relevant allegations of
Plaintiff’s First Amended Complaint (“FAC”). (Docket No. 13.) The Court is not
making findings of fact.
1
3:17-cv-02266-BEN-KSC
1
serving. On July 15, 2015, Plaintiff Toni Welk purchased a bottle of Nutraceutical’s
2
“Biogenesis – Methyl Factors 2 oz.” (“Methyl Factors”)2 Liquid Vitamin B12
3
supplement. The “Supplement Facts” section of the Methyl Factors bottle declares, inter
4
alia, that the serving size of is 1 milliliter (mL), that a single serving contains 1,000
5
micrograms (mcg) of “Vitamin B12 (as Methylcobalamin),” and that each bottle contains
6
59 servings. (FAC ¶ 27.)
7
Plaintiff alleges that Vitamin B12 as Methylcobalamin3 in liquid form “undergoes
8
degradation at an unknown rate.” (Id. ¶ 31.) In 2015, “a reputable supplement analysis
9
center located in California” conducted “scientific testing” on the contents of the Methyl
10
Factors bottle and showed the amount of Methylcobalamin on day 1 of testing as 255.87
11
ug/ml, and on day 11 of testing as 213.16 ug/ml.4 (Id. ¶ 32.) The testing facility received
12
the “sealed” Methyl Factors bottle “in a liquid state in an amber glass bottle at room
13
temperature.” (Id. ¶ 33.) Based on the test results, Plaintiff alleges the Methyl Factors
14
bottle’s label was untrue, false, misleading, and misbranded because a reasonable
15
consumer would expect that each serving from the Methyl Factors bottle would contain
16
1,000 micrograms of Vitamin B12 for each of the 59 servings. However, because the
17
Methyl Factors product “become[s] unstable immediately after opening” and “starts
18
degrading over time,” this does not occur because the amount of Vitamin B12 “becomes
19
negligible and ineffective.” (Id. ¶ 14.)
20
21
22
23
24
25
26
27
28
The Court uses “Methyl Factors” to refer to both Nutraceutical’s “Biogenesis –
Methyl Factors 2 oz.” product, and the actual bottle of “Biogenesis – Methyl Factors 2
oz.” that Plaintiff allegedly purchased.
3
The FAC uses “Vitamin B12” and “Methylcobalamin” interchangeably.
4
The FAC does not discuss the equivalence or measurement conversion, if any, of
the Methylcobalamin’s weight stated as mcg/mL or ug/ml. However, the parties’
briefings do not appear to dispute that Plaintiff’s test results indicated the amount of
Methylcobalamin in the bottle of Methyl Factors Plaintiff purchased was less than 1,000
micrograms. Therefore, because this issue is not germane to the Court’s analysis at this
time, the Court assumes this fact to be true in resolving the instant motion.
2
2
3:17-cv-02266-BEN-KSC
1
On November 11, 2017, Plaintiff filed her initial complaint, to which Nutraceutical
2
responded by filing its first motion to dismiss. (Docket Nos. 1, 8.) Instead of responding
3
to Nutraceutical’s motion, Plaintiff exercised her right to amend her complaint. The FAC
4
asserts four claims for violations of: (1) Cal. Civ. Code §§ 1750 et seq.; (2) Cal. Bus. &
5
Prof. Code §§ 17500 et seq.; (3) Cal. Health & Safety Code §§ 110660 et seq.; and (4)
6
Cal. Bus. & Prof. Code §§ 17200 et seq., and two additional California state-law claims
7
for negligent misrepresentation and intentional misrepresentation.
8
In addition to her individual claims, Plaintiff also seeks to obtain “class wide relief
9
on behalf of all purchasers of any of Defendant’s Products that are substantially similar to
10
the product purchased by Plaintiff (i.e., all of Defendant’s liquid vitamin B12 products,
11
regardless of the brand they are advertised under and the exact amount of liquid B12
12
vitamin advertised per serving).” (FAC ¶ 1 n.1.)
13
Nutraceutical now moves for dismissal pursuant to Rules 12(b)(1) and 12(b)(6) of
14
the Federal Rules of Civil Procedure of all of Plaintiff’s claims on three grounds: 1)
15
Plaintiff’s claims are preempted; 2) Plaintiff’s individual claims are insufficiently
16
pleaded; and 3) Plaintiff lacks standing to assert claims for products she did not purchase.
17
LEGAL STANDARD
18
1.
Rule 12(b)(1)
“It is a fundamental principle that federal courts are courts of limited jurisdiction.”
19
20
Stock W., Inc. v. Confederated Tribes of the Colville Reservation, 873 F.2d 1221, 1225
21
(9th Cir. 1989) (quoting Owen Equip. & Erection Co. v. Kroger, 437 U.S. 365, 374,
22
(1978)). Under Rule 12(b)(1), a party can move a court to dismiss an action for lack of
23
subject matter jurisdiction. Fed. R. Civ. Proc. 12(b)(1). In such a motion, the party
24
asserting jurisdiction bears the burden to establish jurisdiction. See Kokkonen v.
25
Guardian Life Ins. Co. of America, 511 U.S. 375 (1994) (“It is to be presumed that a
26
cause lies outside [federal court] jurisdiction . . . and the burden of establishing the
27
contrary rests upon the party asserting jurisdiction.”) (internal citations omitted).
28
///
3
3:17-cv-02266-BEN-KSC
1
A Rule 12(b)(1) jurisdictional attack may be facial or factual. White v. Lee, 227
2
F.3d 1214, 1242 (9th Cir. 2000). A facial attack asserts that the allegations contained in a
3
complaint are insufficient on their face to invoke federal jurisdiction. See Safe Air v.
4
Meyer, 373 F.3d 1035, 1039 (9th Cir. 2004). A Rule 12(b)(1) motion will be granted if,
5
on the face of the complaint, and when considered in its entirety, the complaint fails to
6
allege facts sufficient to establish subject matter jurisdiction. Id.
7
2.
8
9
Rule 12(b)(6)
Under Federal Rule of Civil Procedure 12(b)(6), a court may dismiss a complaint
if, taking all factual allegations as true, the complaint fails to state a plausible claim for
10
relief on its face. Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009); Bell Atl. Corp. v.
11
Twombly, 550 U.S. 544, 556-57 (2007). Dismissal is appropriate if the complaint fails to
12
state enough facts to raise a reasonable expectation that discovery will reveal evidence of
13
the matter complained of, or if the complaint lacks a cognizable legal theory under which
14
relief may be granted. Twombly, 550 U.S. at 556.
15
DISCUSSION
16
Defendant contends Plaintiff’s claims are preempted by the Food, Drug, and
17
Cosmetic Act (“FDCA”) and Nutrition Labeling and Education Act (“NLEA”) because
18
Plaintiff does not allege the Methyl Factors product was tested using the methods
19
established by the Food and Drug Administration (“FDA”).5 The Court agrees.
20
A.
21
Preemption Under the FDCA & NLEA Generally
The FDCA “governs the labeling of food, drugs, cosmetic products and medical
22
devices.” Lilly v. ConAgra Foods, Inc., 743 F.3d 662, 664-65 (9th Cir. 2014). In 1990,
23
Congress amended the FDCA by enacting the NLEA, “which established uniform food
24
labeling requirements[.]” Id. The NLEA contains an express preemption provision that
25
preempts state-law food-labeling requirements that are “not identical to the requirements
26
27
28
5
After Congress enacted the FDCA, the FDA was established. 21 U.S.C. § 393(a).
4
3:17-cv-02266-BEN-KSC
1
of section 343(r).” 21 U.S.C. § 343-1(a)(5). The phrase “not identical to” means “that
2
the State requirement directly or indirectly imposes obligations or contains provisions
3
concerning the composition or labeling of food [that] . . . [a]re not imposed by or
4
contained in the applicable [federal regulation] . . . or [d]iffer from those specifically
5
imposed by or contained in the applicable [federal regulation].” Lilly, at 665 (quoting 21
6
C.F.R. § 100.1(c)(4)) (alterations in original). These provisions apply to dietary
7
supplements because dietary supplements are deemed to be “food” for purposes of the
8
FDCA. 21 U.S.C. § 321(ff).
Under this framework, state-law claims are generally preempted only “where
9
10
application of state laws would impose more or inconsistent burdens on manufacturers
11
than the burdens imposed by the FDCA.” Gallagher v. Bayer AG, No. 14-CV-04601-
12
WHO, 2015 WL 1056480, at *4 (N.D. Cal. Mar. 10, 2015)). Conversely, “[i]f a lawsuit
13
asserts that a manufacturer has violated the FDCA (as amended by NLEA) and does not
14
seek to impose additional or contrary burdens to those imposed under the FDCA, the
15
claims raised under state law are not preempted.” Id., at *4 (citing Salazar v. Honest Tea,
16
Inc., No. 2:13-CV-02318-KJM, 2014 WL 2593601, at *4 (E.D. Cal. June 10, 2014)). In
17
short, to avoid preemption under 21 U.S.C. § 343-1(a), “the plaintiff must be suing for
18
conduct that violates the FDCA” but not “solely because the conduct violates the FDCA,
19
else his claim would be impliedly preempted under [21 U.S.C. §] 337(a).” Trazo v.
20
Nestle USA, Inc., No. 5:12-CV-2272-PSG, 2013 WL 4083218, at *5 (N.D. Cal. Aug. 9,
21
2013) (emphasis in original omitted).
22
B.
23
Federal Labeling Requirements for Vitamin B12
Under 21 U.S.C. § 343(a), a dietary supplement is misbranded if “its labeling is
24
false or misleading in any particular.” 21 U.S.C. § 343(a). Federal regulations
25
established by the FDA require that the “nutrition information on the label” include a
26
“declaration of vitamins and minerals . . . listed in paragraph (c)(8)(iv) . . . as a statement
27
of the amount per serving . . . as described in this paragraph, calculated as a percent of the
28
RDI and expressed as a percent of the Daily Value, when they are added as a nutrient
5
3:17-cv-02266-BEN-KSC
1
supplement, unless otherwise stated as quantitative amount by weight and percent of the
2
Daily Value.”6 See 21 C.F.R. § 101.9(c)(8). Vitamin B12 is one of the listed vitamins.
3
See 21 C.F.R. § 101.9(c)(8)(iv). The “quantitative amount” of Vitamin B12 “shall be the
4
amount . . . included in one serving” using micrograms as the unit of measurement. See
5
21 C.F.R. § 101.9 subds. (c)(8)(iii)-(c)(8)(iv).
6
Compliance with the labeling requirements under 21 C.F.R. § 101.9(c)(8) is
7
determined based on a specific testing methodology described in 21 C.F.R. § 101.9(g)(2),
8
which provides:
9
The sample for nutrient analysis shall consist of a composite of
12 subsamples (consumer units), taken 1 from each of 12
different randomly chosen shipping cases, to be representative
of a lot. Unless a particular method of analysis is specified in
paragraph (c) of this section, composites shall be analyzed by
appropriate methods as given in the “Official Methods of
Analysis of the AOAC International,” or, if no AOAC method
is available or appropriate, by other reliable and appropriate
analytical procedures.
10
11
12
13
14
15
16
21 C.F.R. § 101.9(g)(2). Thus, in order to comply with federal labeling requirements, the
17
Methyl Factors products’ label’s statement that it contains 1,000 micrograms of Vitamin
18
B12 as Methylcobalamin must be based on results of testing conducted in accordance
19
with 21 C.F.R. § 101.9(g)(2).
20
C.
Whether Plaintiff’s Claims are Preempted
21
Each of Plaintiff’s claims are predicated on Plaintiff’s ability to prove that, once
22
opened, Defendant’s Biogenesis – Methyl Factors 2 oz. product does not contain 1,000
23
micrograms of Methylcobalamin per 1 milliliter serving for each of the 59 servings
24
throughout the duration of its shelf life. Indeed, the FAC is careful to avoid allegations
25
26
27
28
For “dietary supplements,” such as the Methyl Factors products, the “nutrition
information” must be “enclosed in a box” titled “Supplement Facts.” See 21 C.F.R. §
101.36(e).
6
6
3:17-cv-02266-BEN-KSC
1
that the Methyl Factors bottle did not contain the stated amount of Vitamin B12 at the
2
time of manufacturing lest her claim be impliedly preempted under 21 U.S.C. § 337(a).
3
See Trazo, 2013 WL 4083218, at *5.
4
Plaintiff’s theory is that the Methyl Factors label is misleading because it fails to
5
disclose that the product “become[s] unstable upon opening and degrade[s] over time,
6
such that the amount of B vitamins becomes negligible and ineffective.” (FAC ¶ 40.)7
7
To establish this theory, Plaintiff alleges:
8
In 2015, scientific testing by a reputable supplement analysis
center located in California of [Methyl Factors] (labeled as
“Serving Per Container: 59” with a “Serving Size 1ml”)
revealed that on day 1 of testing, the level of Methylcobalamin
in the product was 255.87 ug/ml, and on day 11 of testing it
was213.16 ug/ml.
9
10
11
12
The product was received by the testing facility in a liquid state
in an amber glass bottle at room temperature, in a sealed bottle.
13
14
15
(FAC ¶¶ 32-33.) These are the only factual allegations supporting Plaintiff’s conclusion
16
that the Methyl Factors products “become unstable immediately upon opening,” and
17
“starts degrading over time such that the amount of vitamin B12 becomes negligible and
18
ineffective.” (Id. ¶ 14.)
19
Defendant contends Plaintiff’s claims are preempted because the testing
20
methodology referenced above does not comply with 21 C.F.R. § 101.9(g)(2), and
21
therefore Plaintiff ultimately seeks to seek to impose obligations under California state
22
law that conflict with those set forth in the FDCA and NLEA. Specifically, Defendant
23
points out that Plaintiff’s own allegations indicate only one bottle of the Methyl Factors
24
25
Plaintiff’s opposition improperly attempts to argue a new theory of liability, i.e.,
that Defendant failed its “obligation to design its packaging in such a way that the
product would not be subjected to degradation.” (Opp’n at p. 9.) This theory was not
previously alleged in the FAC, and therefore the Court does not consider Plaintiff’s
arguments regarding this theory.
7
26
27
28
7
3:17-cv-02266-BEN-KSC
1
product was tested, from which the Court may draw an inference that the testing method
2
mandated by 21 C.F.R. § 101.9(g)(2) was not followed. Defendant further cited a
3
number of district court cases with similar facts who all dismissed a plaintiff’s claims as
4
preempted in failing to allege compliance with 21 C.F.R. § 101.9(g)(2). (See Mot. at pp.
5
9-12.)
6
In opposition, Plaintiff agrees that her claim under California Health & Safety
7
Code § 10660 (“the Sherman Act”) for label misbranding is identical to 21 U.S.C.
8
§ 343(a) and that “they are identical in language and standards.” (Opp’n at p. 8.)
9
However, she nevertheless argues it would be “illogical” and “unfair” to require her to
10
use testing that complies with 21 C.F.R. § 101.9(g)(2) because her claim is based on the
11
Methyl Factors products’ “rapid degradation,” which is “measured by one sample’s
12
change over a period of time.” (Opp’n at p. 12.) Plaintiff cites no authority for this
13
conclusion, and the Court is not persuaded by its premise.
14
In the words of one district court: “where, as here, an FDA regulation provides that
15
the question of compliance must be determined using the method specified therein, a state
16
law claim that seeks to establish a violation of such regulation by a different methodology
17
is preempted.” Mee v. I A Nutrition, Inc., No. C-14-5006 MMC, 2015 WL 2251303, at
18
*4 (N.D. Cal. May 13, 2015) (citing Salazar, 2014 WL 2593601, at *1, 6 (granting
19
motion to dismiss claim that defendant’s teas “did not contain the amount of antioxidants
20
represented on their labels,” where plaintiff failed to allege the “independent testing” on
21
which she relied had been conducted in accordance with § 101.9(g)(2)); Vital v. One
22
World Co., 2012 U.S. Dist. LEXIS 186203, at *2, 13-18 (C.D. Cal. November 30, 2012)
23
(finding defendant entitled to summary judgment on claim defendant made
24
“overstatement of the magnesium and sodium content” of its coconut water product,
25
where plaintiffs failed to offer evidence to show report on which they relied had been
26
conducted in accordance with § 101.9(g)(2)); Burke v. Weight Watchers Int’l, Inc., 983 F.
27
Supp. 2d 478, 480, 483 (D.N.J. 2013) (granting motion to dismiss claim alleging
28
defendant’s ice cream bars’ “calorie content [was] 20%-36% greater than the calorie
8
3:17-cv-02266-BEN-KSC
1
content listed on the box,” where plaintiff, inter alia, failed to allege the “independent
2
laboratory tests” on which she relied were conducted in accordance with the methodology
3
set forth in § 101.9(c)(1)(I))).
4
In sum, in order for Plaintiff to ultimately prove her claims that the Methyl Factors
5
products “become unstable immediately after opening” and “start[] degrading over time”
6
such that the Methyl Factors label is misleading and/or misbranded, the Methyl Factors
7
products must be tested. As discussed above, federal law preempts how the testing must
8
be conducted. Plaintiff’s opposition effectively concedes that the “scientific testing”
9
upon which her claims rely does not comply with the requirements for testing under 21
10
C.F.R. § 101.9(g)(2). And, even construing the factual allegations in a light most
11
favorable to Plaintiff, the Court is unable to draw this inference. As a result, the Court
12
GRANTS Defendant’s motion to dismiss on this ground.8
13
14
CONCLUSION
For the forgoing reasons, the Court finds Plaintiff’s claims are preempted by the
15
FDCA and NLEA, and Defendant’s motion to dismiss Plaintiff’s First Amended
16
Complaint is GRANTED. However, the Court shall provide Plaintiff with an
17
opportunity to amend her pleading to correct the deficiencies identified in this Order.
18
Therefore, Plaintiff’s FAC is DISMISSED without prejudice. If Plaintiff elects to
19
amend her pleading, it must be filed by no later August 17, 2018.
20
IT IS SO ORDERED.
21
22
Dated: August 10, 2018
23
24
25
26
27
Because the Court finds Plaintiff’s claims preempted by the FDCA and NLEA, it
declines to rule on Defendant’s remaining arguments.
8
28
9
3:17-cv-02266-BEN-KSC
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
Why Is My Information Online?